CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

SMid Biotech Analyst Joseph holds a conference call with CEO Evans on November 12 at 2 pm hosted by JPMorgan.Webcast Link Published first on ...

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...

Leerink Partners has recently raised Beam Therapeutics Inc (BEAM) stock to Outperform rating, as announced on November 6, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had ...

Fintel reports that on November 6, 2024, Leerink Partners upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Analysts estimate that Beam Therapeutics will report an earnings per share (EPS) of $-1.16. The announcement from Beam Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating today. Patrick Trucchio has ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had ...